Saturday 17 October 2026
Export IMNM’s income statement to Excel — free account
Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024. In the quarter to June 2026, revenue grew 69.8%, EPS fell 30.0% and free cash flow fell 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
16.47
0.93
−5.34%
Follow IMNM
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 9.28 | 9.50 | 2.09 | 2.40 | 8.97 | 5.15 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 16.77 | 63.78 | 14.11 | 11.25 | 30.96 | 25.30 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 21 | 23 | 39 | 37 | 55 | 118 | 177 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.08 | 0.04 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 14 | 9 | 7 | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | (8) | (10) | (18) | (25) | (37) | (107) | (293) | (212) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (761.92) | (3,240.38) | (3,059.99) | |||||
| Net income | — | 0 | (8) | (10) | (18) | (25) | (37) | (107) | (293) | (212) | |||||
| Depreciation | — | — | 1 | 1 | 1 | 1 | 1 | 0 | (1) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.71 | 0.15 | 0.08 | ||||
| Earnings | — | — | (7.22) | (9.55) | (5.26) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) | |||||
| Cash flow | — | — | (6.81) | (8.78) | (3.58) | (1.58) | (2.37) | (0.38) | (1.89) | (2.19) | |||||
| Capex | — | — | (0.21) | (0.21) | (0.17) | (0.01) | (0.02) | (0.04) | (0.12) | (0.11) | |||||
| Free cash flow | — | — | (7.02) | (8.99) | (3.75) | (1.59) | (2.39) | (0.42) | (2.01) | (2.30) | |||||
| Book value | — | — | 2.12 | 2.98 | 12.20 | 4.18 | 1.37 | 6.04 | 3.09 | 7.26 | |||||
| Shares, m | — | — | 1 | 1 | 3 | 12 | 12 | 20 | 59 | 87 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 15.59 | 68.88 | 149.04 | |||||
| P/B | — | — | — | — | — | — | — | 1.82 | 3.44 | 2.96 | |||||
| EV/Sales | — | — | — | — | — | — | — | 5.77 | 44.90 | 97.17 | |||||
| EV/FCF | — | — | — | — | — | — | — | (9.62) | (3.44) | (6.10) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (7) | (10) | (12) | (18) | (29) | (8) | (111) | (191) | ||||
| Capex | — | — | 0 | 0 | (1) | 0 | 0 | (1) | (7) | (10) | |||||
| Free cash flow | — | — | (8) | (10) | (13) | (18) | (29) | (8) | (118) | (201) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 1 | 1 | 40 | 47 | 15 | 123 | 167 | 616 | ||||
| Total debt | — | — | 1 | 1 | 1 | — | 0 | — | — | — | |||||
| Net debt | — | — | 0 | (2) | (39) | (49) | (20) | (138) | (217) | (653) | |||||
| Shareholders’ equity | — | — | 2 | 3 | 41 | 48 | 17 | 120 | 181 | 634 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (352.74) | (219.69) | (71.95) | (48.24) | (91.54) | (123.77) | (150.71) | (46.00) | ||||
| ROIC | — | — | (257.14) | (503.31) | (368.60) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 25.79 | 34.34 | (624.22) | (55.20) | (115.73) | (156.45) | (194.63) | (52.09) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2025
Charts ten years each
Immunome, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IRON Disc Medicine, Inc. | $2.2B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FTRE Fortrea Holdings Inc. | $2.2B | — (loss-making) | — (loss-making) | −4.52% (below 0%: shrinking) | n/m | +53.15% (above 0%: growing) | 20.52% | 2.18% | Compare |
| NVAX Novavax, Inc. | $2.1B | — (loss-making) | — (loss-making) | −76.30% (below 0%: shrinking) | n/m | +42.95% (above 0%: growing) | 74.87% | (96.84%) | Compare |
| VCEL Vericel Corporation | $2.1B | 83.6× | 76.8× | +22.48% (above 0%: growing) | n/m | +17,503.70% (above 0%: growing) | 72.82% | 0.56% | Compare |
| PHVS Pharvaris N.V. | $2.1B | — (loss-making) | — | — | n/m | −17.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VERA Vera Therapeutics, Inc. | $2.1B | — (loss-making) | — | — | n/m | −82.47% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IMNM Immunome, Inc. | $2.1B | — (loss-making) | — (loss-making) | +69.84% (above 0%: growing) | n/m | −26.96% (below 0%: shrinking) | 100.00% | 0.00% | |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.0B | — (loss-making) | — (loss-making) | −95.35% (below 0%: shrinking) | +198.85% (above 0%: growing) | +18.22% (above 0%: growing) | 25.95% | (982.91%) | Compare |
| AGIO Agios Pharmaceuticals, Inc. | $1.9B | — (loss-making) | — (loss-making) | +259.25% (above 0%: growing) | n/m | +24.97% (above 0%: growing) | 93.30% | (247.07%) | Compare |
| Median of peers | $2.1B | — | — | −4.52% | — | +21.60% | 23.24% | 0.00% |
Immunome, Inc. (IMNM) key facts
- Concern: Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Immunome, Inc. (IMNM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, IMNM traded at $16.47, a market capitalization of $2.1 billion.
- Return on equity was −52.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 21.57 (safe zone) for fiscal 2025.